TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the safety and efficacy results from Part I of the MATINS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results